ReGelTec Receives CE Mark for HYDRAFIL® System to Treat Chronic Low Back Pain
CE Mark approval for the HYDRAFIL System was granted based on a clinical study of 75 patients that showed that those treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability.
CE Mark approval for the HYDRAFIL System was granted based on a clinical study of 75 patients that showed that those treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability. Results demonstrated a more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores after HYDRAFIL treatment, with reductions sustained for two years in the 63 patients that have completed their two-year follow-up visit.
'Chronic low back pain is a debilitating condition that impacts millions of people every year. Degenerative disc disease, which is the largest driver of chronic low back pain, is especially challenging to treat and manage because there are limited treatment options between conservative care and more invasive surgeries,' said Dr. Olivier Clerk-Lamalice, MD, FIPP, a fellowship-trained interventional radiologist and chief executive officer of Beam Radiology in Calgary, Canada. 'After following 35 patients treated with HYDRAFIL over the last three years, I've witnessed how effective this minimally invasive outpatient procedure is in reducing pain and disability. HYDRAFIL addresses a massive treatment gap for degenerative disc disease patients looking to avoid major spine surgery, and we are excited to start enrolling patients in the HYDRAFIL-D U.S. pivotal study.'
More than 1 in 10 U.S. adults suffer from chronic low back pain. 1 About 42% of this population, or more than 10 million Americans, has degenerative disc disease 2, a condition which is the largest contributor to chronic low back pain where intervertebral discs in the spine deteriorate and lose their height and volume. Degenerating discs cause vertebrae to move abnormally and inflame surrounding spinal structures, muscles, joints and nerves, resulting in pain in the back and sometimes the leg.
Performed in an outpatient procedure under local anesthesia, ReGelTec's HYDRAFIL® System injects a permanent hydrogel into a degenerated disc to fill cracks and tears and recruit water into the disc to restore natural biomechanics and provide pain relief. When the hydrogel implant solidifies in the disc, it distributes the load and strain felt in that intervertebral segment to improve function and reduce the pain signaling to the brain.
Data used to secure CE Mark also led the FDA to approve an investigational device exemption (IDE) for ReGelTec's U.S. pivotal study of its HYDRAFIL System. The HYDRAFIL-D study is currently enrolling patients at eight sites in the U.S. and will be used to support U.S. regulatory approval. The study is a 225-patient, multicenter, single-blinded, randomized, controlled trial that includes an interim safety analysis when the first sixty patients complete their 6-month follow-up visit.
'Receiving CE Mark for the HYDRAFIL System is another major milestone for ReGelTec,' said Bill Niland, Co-Founder and CEO, ReGelTec. 'We are leveraging this momentum to drive enrollment in the HYDRAFIL-D pivotal study required for FDA approval, and look forward to securing additional capital to support ongoing investment in the U.S. and globally.'
ReGelTec is a clinical-stage privately held biomedical company dedicated to developing and commercializing a percutaneous hydrogel implant for the treatment of chronic low back pain due to degenerative disc disease. ReGelTec's HYDRAFIL® System is an outpatient disc augmentation procedure where a permanent hydrogel is injected into a degenerated disc to fill cracks and tears and recruit water into the disc to restore natural biomechanics and provide pain relief. For more information, please visit https://regeltec.com/.
1 Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PMID: 26991822; PMCID: PMC5027174.
2 Michael J. DePalma, Jessica M. Ketchum, Thomas Saullo, What Is the Source of Chronic Low Back Pain and Does Age Play a Role?, Pain Medicine, Volume 12, Issue 2, February 2011, Pages 224–233, https://doi.org/10.1111/j.1526-4637.2010.01045.x
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Business Wire
11 hours ago
- Business Wire
MedCity News Report Reveals Employers are Turning to AI-Powered, Clinically Integrated Independent Healthcare Navigation to Combat Rising Costs
DUBLIN, Ohio--(BUSINESS WIRE)--As employers face mounting pressure to improve health outcomes while managing rising costs, a new report sponsored by Quantum Health reveals a significant shift in how benefit consultants are advising self-insured employers to build and evaluate healthcare benefit strategies. The 2025 Benefits Sentiment Index, conducted in partnership with MedCity News, offers a data driven look into the top challenges and emerging priorities shaping the benefits landscape. "Independent navigation is accelerating as a central benefits strategy, not only to improve the member experience, but to lower costs, improve value on investment and seamlessly integrate AI-driven innovations with compassionate, human-centered care." Share Now in its third year, the Index surveyed more than 120 experienced benefit consultants and uncovered a growing demand for independent, clinically integrated navigation models and a rising dissatisfaction with traditional carrier-provided services. Among the key findings: 68% of surveyed consultants guide clients away from navigation solutions tied to insurance carriers, instead recommending independent partners citing the need for a stronger member experience, clinical integration and transparency in cost savings. 87% of surveyed consultants report advising on GLP-1 drug coverage, with most recommending restrictions and measurable outcomes to ensure cost-effectiveness. The influence of AI continues to grow, with 72% of consultants surveyed counseling clients on its use in benefits — up significantly from the prior year. 'We're excited to once again collaborate with MedCity News on the Benefits Sentiment Index, bringing forward the key priorities shaping the healthcare benefits landscape,' said Dayne Williams, CEO of Quantum Health. 'This year's findings highlight how independent healthcare navigation is accelerating as a central healthcare benefits strategy — not only to simplify and improve the member healthcare experience, but also to lower costs, improve value on investment and seamlessly integrate AI-driven innovations with compassionate, human-centered care.' Williams added, "As the only navigation solution that engages continuously with providers from the member's first moment of need, we take immediate action to guide care decisions in real time. Leveraging advanced AI and our proprietary Real-Time Intercept® platform, we proactively identify members at critical moments and connect them to the right care at the right time. This approach combines clinical expertise with accelerated intervention — delivering independently validated results, improved health outcomes and a better experience for members.' The report also calls attention to gaps in engagement and personalization, with half of consultants reporting that their clients struggle with fragmented care coordination, lack of centralized access and difficulty engaging employees. Consultants are increasingly seeking solutions that integrate clinical care teams, embed AI for proactive risk detection, and provide seamless connections to behavioral health and social determinants of health support. 'At MedCity News, we're committed to surfacing insights that drive smarter healthcare decisions, and this year's Index does exactly that,' said Ken Montgomery, publisher of MedCity News. 'The data reveals a clear call to action: self-insured employers and their consultants are demanding more from navigation solutions — more clinical integration, more actionable data and more alignment with evolving technologies like AI. We're proud to partner with Quantum Health to spotlight these critical shifts and help advance the conversation on what effective benefits strategy looks like today.' 'The takeaway is clear,' said Williams. 'Employers are no longer satisfied with the status quo. The next chapter of healthcare navigation must be clinically integrated, AI-enabled and relentlessly focused on driving measurable results.' The full 2025 Benefits Sentiment Index is available for download here. About MedCity News MedCity News is the go-to digital destination for B2B healthcare innovation news, informing decision-makers of trends in the healthcare industry. MedCity News produces dynamic and unique innovation-focused events for the entire healthcare ecosystem, gathering experts from across disciplines to address the challenges facing the industry. MedCity News also produces the Debunked videocast, as well as several podcasts: MedCity Pivot, MedCity Moves and MedCity FemFwd. MedCity News is owned by Breaking Media, a network of websites, e-newsletters, events and social media channels for influential, affluent business communities. To learn more visit MedCity News. About Quantum Health Celebrating 25 years of innovation, Quantum Health is a leading consumer healthcare navigation and care coordination company. Its Real-Time Intercept® platform identifies early intervention opportunities to improve engagement, outcomes, and cost efficiency. Based in Dublin, Ohio, Quantum Health has earned national recognition for growth and workplace culture, including honors from FORTUNE, Inc. 5000, and the Women Presidents' Organization. To learn more, visit and connect on LinkedIn.
Yahoo
14 hours ago
- Yahoo
Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP)
Papzimeos, the first-ever treatment approved for RRP is a moment for celebration and reflection FORT WORTH, Texas, August 15, 2025--(BUSINESS WIRE)--The Recurrent Respiratory Papillomatosis Foundation (RRPF) is excited to share the news that the U.S. Food and Drug Administration (FDA) has granted full approval to Precigen's Papzimeos (zopapogene imadenovec-drba) under Priority Review for the treatment of adults with Recurrent Respiratory Papillomatosis (RRP). Papzimeos is the first and only FDA-approved treatment for RRP. (See FDA's announcement here) A moment of profound healing for the RRP Community This is truly a remarkable day – the culmination of decades of advocacy, resilience, and unwavering commitment from patients, families, researchers, and supporters. The approval of the first non-surgical treatment for adults with RRP marks not only a scientific milestone, but an inflection point for the entire RRP community. We extend our deepest gratitude to the many individuals and institutions who helped make this breakthrough possible – from the investigators, NIH collaborators, and clinicians who advanced the science, to the industry partners, whose investment and commitment to this community helped bring this treatment to approval. The FDA's announcement is also a deeply personal victory for every voice that has spoken up, every surgery endured, and every hope held steadfast. At RRPF, we are honored to walk alongside this community, championing awareness, supporting research, and amplifying the lived experiences of those affected by this rare disease. We celebrate the light this approval brings and recommit ourselves to the journey ahead, ensuring that patients of every age and living beyond the U.S. can one day access safe, effective and nonsurgical treatments. "For decades, our community has persevered through an isolating journey of countless surgeries, silence, and uncertainty. Yet while we continued to breathe, we continued to hope. Today, our hope is realized. Today, with the approval of Papzimeos our hope is no longer a dream, it's a reality," said Kim McClellan, President of RRPF. "This is a moment of profound healing, not just for the body, but for the spirit of every adult living with RRP. We finally have an FDA-approved treatment that targets the root cause of RRP and with it, the chance for many members of our community to reclaim lives unencumbered by RRP." Quick facts about Papzimeos (zopapogene imadenovec-drba): The first and only FDA-approved treatment for RRP Approved for adults with RRP The only treatment to target the underlying cause of RRP Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11 Delivered via four subcutaneous injections over a 12-week interval Patients can access Papzimeos SUPPORT for personalized services including insurance navigation, financial assistance, and ongoing access support, by calling (866) 827-8180. For Precigen's full release here: Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis For those interested in learning more about resources available to individuals affected by RRP, visit Renewed hope and continued commitment The FDA full approval of Papzimeos is a monumental step forward for the RRP community, but it is not the final destination. RRPF remains deeply committed to advancing research for all patients – including pediatric patients, who continue to face burdens of this disease without an approved therapeutic option, and patients around the world. This milestone fuels our resolve and fortifies our determination to see a future where all people living with RRP have the same hope realized. With strengthened movement, we will continue to advocate, collaborate, and push for the science that brings healing at every age and to every corner of the world. About RRPF The Recurrent Respiratory Papillomatosis Foundation (RRPF) was born from a parent's urgent need to understand and confront a rare, chronic, and potentially life-threatening disease affecting their child. Since 1991, RRPF has been a lifeline for patients and families navigating the isolating journey of RRP – offering connection, advocacy, and hope. What began as a grassroots effort has grown into a mission-driven organization united by the voices of parents, patients, and researchers. RRPF provides vital resources including access to the latest research, updates on clinical trials and medical meetings, and a supportive community for those affected by RRP. The foundation has played a pivotal role in advancing scientific understanding of RRP – contributing to research as authors, funders, and collaborators across multiple studies and initiatives. RRPF honors the legacy of those like Jennifer Woo, a former president of RRPF whose life and career were dedicated to curing RRP, and continues to drive forward research, awareness, and support for all those impacted. While we breathe, we hope. Learn more here: View source version on Contacts Media:Kim McClellan, President RRPF(331) 826-9050kimmc@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
